INVO Bioscience (INVO) Tops Q3 EPS by $1.50

INVO Bioscience (NASDAQ: INVO) reported Q3 EPS of ($0.70), $1.50 better than the analyst estimate of ($2.20). Revenue for the quarter came in at $970 thousand versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on INVO Bioscience (INVO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery